OralParenteralDosed ingredientTherapeutic flag Cosmetic cross-reference

Ergocalciferol

CAS 50-14-6

Ergocalciferol (CAS 50-14-6) is a Phase 4 pharmaceutical compound with 3 bioactivity targets and 9,306 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

9,306

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Ergocalciferol

CAS Number

50-14-6

UNII

VS041H42XC

InChIKey

MECHNRXZTMCUDQ-RKHKHRCZSA-N

ChEMBL ID

CHEMBL1536

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

dosed ingredientnatural productoralparenteraltherapeutic flag

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL1536 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE NLM DailyMed 2 label rows

Drug Label Active Ingredients

Active ingredient and active moiety rows from source drug product labels.

Product	Ingredient	Active Moiety	Effective
Ergocalciferol	ERGOCALCIFEROL VS041H42XC	ERGOCALCIFEROL	20260505
Ergocalciferol	ERGOCALCIFEROL VS041H42XC	ERGOCALCIFEROL	20260505

SOURCE EMBL-EBI ChEMBL 8 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	AC50	28688.582142857143 nM	28	-
-	Potency	28742.55 nM	12	-
-	IC50	57800 nM	6	-
-	GI50	66850 nM	2	-
-	EC50	3800 nM	1	-
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial Enzyme	-	-	-	Homo sapiens
Vitamin D3 receptor Nuclear hormone receptor	AGONIST	-	-	Homo sapiens
Vitamin D 25-hydroxylase Enzyme	-	-	-	Homo sapiens

SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Toxicity to various agents	543	1711.884	10070863
Completed suicide	200	1042.492	10010144
Drug interaction	1059	975.343	10013710
Drug abuse	114	785.93	10013654
Acute kidney injury	1931	665.02	10069339
Product dose omission issue	4366	635.672	10084406
Multiple sclerosis relapse	1294	623.99	10048393
Fatigue	12375	622.575	10016256
Intentional overdose	76	579.592	10022523
Overdose	418	576.927	10033295
Muscle spasms	2928	457.409	10028334
Thrombocytopenia	1008	429.196	10043554
Back pain	4179	383.588	10003988
Headache	8020	377.835	10019211
Febrile neutropenia	835	349.535	10016288
Multiple organ dysfunction syndrome	257	345.353	10077361
Cardio-respiratory arrest	199	324.099	10007617
Neutropenia	1313	321.805	10029354
Drug ineffective	8289	317.599	10013709
Hepatic function abnormal	86	316.34	10019670
Infective pulmonary exacerbation of cystic fibrosis	449	312.219	10070608
Hypoaesthesia	2669	308.745	10020937
Hypotension	2091	306.285	10021097
Pain in extremity	4617	301.028	10033425
Cardiac arrest	521	298.336	10007515
Cardiac failure	495	297.817	10007554
Suicide attempt	168	288.278	10042464
Depressed level of consciousness	189	279.395	10012373
Hyperkalaemia	279	261.551	10020646
Diarrhoea	9754	259.047	10012735
Fall	5580	251.556	10016173
Multiple sclerosis	612	251.52	10028245
Hyponatraemia	621	248.999	10021036
Sinusitis	2926	248.375	10040753
Memory impairment	1786	247.891	10027175
Rhabdomyolysis	243	245.74	10039020
Drug reaction with eosinophilia and systemic symptoms	81	244.28	10073508
Feeling abnormal	2337	236.771	10016322
Foetal exposure during pregnancy	281	227.237	10071404
Septic shock	394	221.095	10040070
Muscle spasticity	558	220.375	10028335
Pancytopenia	634	217.252	10033661
Electrocardiogram QT prolonged	234	216.903	10014387
Sopor	4	213.013	10058709
Insomnia	3289	210.764	10022437
Interstitial lung disease	365	203.411	10022611
Lactic acidosis	130	203.2	10023676
Respiratory failure	751	197.598	10038695
Metabolic acidosis	191	196.69	10027417
Influenza like illness	1207	194.388	10022004

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 3 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
Ergocalciferol	4018	SU	MTHSPL
ERGOCALCIFEROL	4018	SU	MTHSPL
ergocalciferol	4018	IN	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Ergocalciferol used for in pharmaceutical contexts?

Ergocalciferol (CAS 50-14-6) appears in DailyMed active-ingredient label rows, including Ergocalciferol.

What are the known adverse events for Ergocalciferol?

Ergocalciferol has 9,306 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Toxicity to various agents, Completed suicide, Drug interaction, Drug abuse, Acute kidney injury. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Ergocalciferol also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Ergocalciferol with EU status "permitted".

What clinical phase is Ergocalciferol in?

Ergocalciferol is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Ergocalciferol?

Ergocalciferol has 8 bioactivity rows in this page query. Rendered target entries include 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor, Vitamin D 25-hydroxylase.